Bio Plus Co

Bio Plus Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Bio Plus Co (099430.KQ) as of Nov 22, 2026 is -10.07. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -3.94 — a change of 155.53% (lower).

EV/FCF

-10.07

YoY

155.53%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Bio Plus Co is 2025 -10.07 . EV/FCF (Enterprise Value to Free Cash Flow) of Bio Plus Co was 2024 -3.94 . It decreases by 155.53% lower compared to the previous year.

The Bio Plus Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
136.78 KRW
Jan 1, 2019
-210.99 KRW
Jan 1, 2020
35.11 KRW
Jan 1, 2021
-144.32 KRW
Jan 1, 2022
38.61 KRW
Jan 1, 2023
-49.50 KRW
Jan 1, 2024
-3.94 KRW
Jan 1, 2025
-10.07 KRW
The Bio Plus Co EV/FCF history
YEAREV/FCFYoY
-10.07+155.53%
-3.94-92.04%
-49.50-228.22%
38.61-126.75%
-144.32-511.10%
35.11-116.64%
-210.99-254.25%
136.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Bio Plus Co is -10.07 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Bio Plus Co changed from -3.94 to -10.07, representing a 155.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bio Plus Co

All Key Metrics — Bio Plus Co